Vertex (VRTX) legal chief sells 978 shares under 10b5-1 plan

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Joy Liu, EVP and Chief Legal Officer, sold 978 shares of Common Stock in an open-market transaction on April 1, 2026, at an average price of $449.17 per share. The sale was made under a company-approved Rule 10b5-1 trading plan entered into on November 25, 2025.

Following this planned sale, Liu directly holds 21,833 Vertex shares. The filing characterizes this as a routine insider transaction executed pursuant to a pre-arranged trading plan rather than a discretionary trade based on short-term market views.

Insider Trade Summary 10b5-1

Net Seller: 978 shares ($439,288)

Net Sell 1 txn

Insider Liu Joy

Role EVP and Chief Legal Officer

Sold 978 shs ($439K)

Type	Security	Shares	Price	Value
Sale	Common Stock	978	$449.17	$439K

Holdings After Transaction: Common Stock — 21,833 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 978 shares Sale price: $449.17 per share Shares held after transaction: 21,833 shares +1 more

4 metrics

Shares sold 978 shares Open-market sale on April 1, 2026

Sale price $449.17 per share Average sale price for Common Stock

Shares held after transaction 21,833 shares Direct ownership following reported sale

Reported net share change -978 shares Net-sell direction in transaction summary

Key Terms

Rule 10b5-1, open-market sale, Common Stock, Form 4, +1 more

5 terms

Rule 10b5-1 regulatory

"Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

trading plan financial

"company approved trading plan under Rule 10b5-1"

A trading plan is a written set of rules an investor follows about what to buy or sell, when to enter and exit positions, and how much risk to accept—like a travel itinerary that maps the route, stops, and budget before a trip. It matters because it helps remove emotional decisions during market swings, enforces discipline, and makes performance easier to review and improve, reducing the chance of costly impulsive moves.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Liu Joy

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		S(1)		978	D	$449.17	21,833	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Vertex (VRTX) executive Joy Liu report?

Joy Liu reported selling 978 shares of Vertex Common Stock in an open-market transaction. The sale occurred on April 1, 2026, at an average price of $449.17 per share, according to the Form 4 insider trading report for Vertex Pharmaceuticals.

At what price did Joy Liu sell her Vertex (VRTX) shares?

She sold 978 shares at an average price of $449.17 per share. This reflects the per-share consideration received in the open-market sale disclosed, providing a clear view of the transaction value at the time of execution.

How many Vertex (VRTX) shares does Joy Liu hold after this sale?

After the transaction, Joy Liu directly holds 21,833 shares of Vertex Common Stock. This post-transaction ownership level is disclosed in the Form 4 and helps contextualize the size of the reported sale relative to her remaining stake.

Was Joy Liu’s Vertex (VRTX) share sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the transaction was made under a company-approved Rule 10b5-1 trading plan. The plan was entered into on November 25, 2025, indicating the sale was pre-arranged rather than a spontaneous market-timing decision.

What role does Joy Liu hold at Vertex (VRTX)?

Joy Liu serves as Executive Vice President and Chief Legal Officer at Vertex Pharmaceuticals. Her position as a senior officer makes her transactions in Vertex stock reportable on Form 4 as an insider, providing transparency into her trading activity.

Does the Form 4 indicate any derivative transactions for Joy Liu at Vertex (VRTX)?

No derivative transactions are listed in this Form 4 for Joy Liu. The filing shows only a single non-derivative open-market sale of Common Stock and indicates no accompanying option exercises or other derivative activity in this specific report.